Press Release | Mon Apr 22, 2013 7:30am EDT

Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C

* Reuters is not responsible for the content in this press release.